News
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2025.
Zacks.com on MSN2h
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
Received FDA approval of EKTERLY® (sebetralstat)-the first and only oral on-demand treatment for hereditary angioedema; U.S. launch underway - - Six additional global regulatory submissions under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback